Stifel Reiterates Hold on Black Diamond Therapeutic, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino has reiterated a 'Hold' rating on Black Diamond Therapeutic (NASDAQ:BDTX) and maintained a price target of $2.
June 27, 2023 | 4:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Stifel analyst Bradley Canino has reiterated a 'Hold' rating on Black Diamond Therapeutic and maintained a price target of $2.
The news is directly related to Black Diamond Therapeutic (BDTX). The 'Hold' rating and $2 price target maintained by Stifel analyst Bradley Canino suggests a neutral outlook for the stock in the short term. This could potentially impact investor sentiment and trading decisions.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100